267 related articles for article (PubMed ID: 28942789)
1. The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes.
Steen O; Goldenberg RM
Can J Diabetes; 2017 Oct; 41(5):517-523. PubMed ID: 28942789
[TBL] [Abstract][Full Text] [Related]
2. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
Katz PM; Leiter LA
Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
[TBL] [Abstract][Full Text] [Related]
3. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
4. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
Brunton SA
Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
[TBL] [Abstract][Full Text] [Related]
5. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
6. Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines.
Morillas C
Med Clin (Barc); 2016 Nov; 147 Suppl 1():49-53. PubMed ID: 28760226
[TBL] [Abstract][Full Text] [Related]
7. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
Lee S
Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 inhibitors in the treatment of type 2 diabetes.
Hasan FM; Alsahli M; Gerich JE
Diabetes Res Clin Pract; 2014 Jun; 104(3):297-322. PubMed ID: 24735709
[TBL] [Abstract][Full Text] [Related]
9. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
Chrysant SG
Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
[TBL] [Abstract][Full Text] [Related]
10. Considerations for Initiating a Sodium-Glucose Co-Transporter 2 Inhibitor in Adults With Type 2 Diabetes Using Insulin.
Woo VC; Berard LD; Bajaj HS; EkoƩ JM; Senior PA
Can J Diabetes; 2018 Feb; 42(1):88-93. PubMed ID: 28579198
[TBL] [Abstract][Full Text] [Related]
11. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
[TBL] [Abstract][Full Text] [Related]
13. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Brunton S; Reid TS
Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
Schwartz SS; Ahmed I
Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management.
Katsiki N; Mikhailidis DP; Theodorakis MJ
Curr Pharm Des; 2017; 23(10):1522-1532. PubMed ID: 28088910
[TBL] [Abstract][Full Text] [Related]
16. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
J Pharmacol Sci; 2016 Jul; 131(3):198-208. PubMed ID: 27430987
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes.
Woo VC
Can J Diabetes; 2020 Feb; 44(1):61-67. PubMed ID: 31839265
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin for the treatment of Type 2 diabetes.
Gangadharan Komala M; Mather A
Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
[TBL] [Abstract][Full Text] [Related]
19. Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus.
Tang H; Fang Z; Wang T; Cui W; Zhai S; Song Y
Am J Cardiol; 2016 Dec; 118(11):1774-1780. PubMed ID: 27666177
[TBL] [Abstract][Full Text] [Related]
20. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Kuchay MS; Farooqui KJ; Mishra SK; Mithal A
Adv Exp Med Biol; 2021; 1307():213-230. PubMed ID: 32006266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]